Abstract
Parkinson disease (PD) with mild cognitive impairment (PD-MCI) is relatively common in nondemented PD patients, but currently there is no approved treatment. The phase 4 MODERATO is evaluating the effect of 24 weeks of treatment with rasagiline 1 mg/d as add-on therapy in adults with PD-MCI. The trial, which has enrolled 170 patients, is the largest to date to evaluate a treatment for PC-MCI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
